Baxter's BioPharma Solutions contract manufacturing business was recently recognized for the fourth time as Best Contract Manufacturing Organization at the annual Vaccine Industry Excellence (ViE) Awards, held at the World Vaccine Congress in Washington, D.C. The awards recognize the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry over the previous 12 months. This year the Best Contract Manufacturing Organization award honored Baxter's BioPharma Solutions facility in Bloomington, IN.
In addition to manufacturing critical, life-saving products for pharmaceutical and biotechnology companies and providing a variety of services including clinical-to-commercial manufacturing, formulation, and packaging, the BioPharma Solutions facility in Bloomington has expertise in clinical and commercial vaccines, which includes pandemic, preventative and seasonal vaccines for global markets.
BioPharma Solutions, a previous award recipient in 2010, 2011 and 2012, was recognized as Best Contract Manufacturing Organization based on criteria including the range of services provided in niche and core therapeutic areas; methods of performance improvement or introduction of new services; attention to and quality of relationships with clients; milestones reached and final or ongoing outcomes; and building and maintaining existing and long term partnerships.
"The Bloomington team is honored to be recognized by the World Vaccine Congress and the vaccine industry as the best in class," said Susan Easton, plant manager for Baxter's Bloomington, IN, facility. "Being selected as the Best Contract Manufacturing Organization for the fourth time demonstrates our sustainable commitment to serving our customers and patients worldwide."
BioPharma Solutions, with an additional primary contract manufacturing location in Halle (Westfalen), Germany, works with a majority of the top 20 pharmaceutical companies and currently provides sterile contract manufacturing services to more than 60 clients. The business has been a leader in parenteral contract manufacturing for more than 30 years, offering services for aseptic bags, pre-filled syringes, liquid and lyophilized vials and cartridge filling, as well as specialized capabilities for cytotoxics and biologics manufacturing.
The business continues to grow with the ongoing approximate 2,000 square meter capacity expansion of its Halle facility. With cancer incidence on the rise, the expansion is designed to meet clients' growing needs for cytotoxic manufacturing, further enhancing Halle's complete range of resources to support early phase drug formulation through commercial scale-up, product launch and lifecycle management. These efforts follow previous capacity expansions at the facility in 2007 and 2011.
"As a leader in sterile contract manufacturing, we're committed to providing our clients with the strong level of operational and technical expertise upon which they rely," says Nelson Patterson, vice president, sales and marketing for BioPharma Solutions. "We're honored by this industry recognition, and will continue to operate under high quality and reliability standards to deliver a consistently great product that meets customer and patient needs."
For additional information on Baxter's BioPharma Solutions business, please visit www.baxterbiopharmasolutions.com.
For additional information on the World Vaccine Congress 2015, please visit http://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm.